| Larry D Curtis, CRNA | |
|
1010 South 7650 East, Crow Northern Cheyenne Indian Hospital, Crow Agency, MT 59022 | |
| (406) 638-3500 | |
| (406) 638-3569 |
| Full Name | Larry D Curtis |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 1010 South 7650 East, Crow Agency, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952326696 | NPI | - | NPPES |
| 8HJR17 | Other | MT | MEDICARE LODGE GRASS |
| 8HZQ13 | Other | MT | MEDICARE PRYOR |
| 8HZL41 | Other | MT | PRYOR |
| 8HR46X | Other | MT | MEDICARE CROW |
| 8HZH28 | Other | MT | CROW |
| 8HZH38 | Other | MT | LG |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RN19388 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Larry D Curtis, CRNA Rr1 Box 11406, Hardin, MT 59034 Ph: (406) 665-1013 | Larry D Curtis, CRNA 1010 South 7650 East, Crow Northern Cheyenne Indian Hospital, Crow Agency, MT 59022 Ph: (406) 638-3500 |
News Archive
In recent years, Cycloxygenase (COX)-2 has emerged as a therapeutic target for the prevention and treatment of various types of cancers.
A Melbourne researcher will take an important first step in tailoring rehabilitation and support services to the estimated 142,500 working-age Australians living with the impact of stroke.
Kensey Nash Corporation, a leading medical technology company that provides innovative resorbable biomaterial technology for a wide range of medical procedures, today announced that it has received 510(k) clearance for its first extracellular matrix (ECM) product, Medeor(TM) Matrix, from the U.S. Food and Drug Administration.
AMRA, the international leader in body composition analysis, and Siemens Healthineers have announced a new agreement that will see AMRA's cloud-based, body composition analysis integrated into Siemens Healthineers Digital Ecosystem.
Aclaris Therapeutics, Inc. today announced positive results from a Phase 2 clinical trial of the Company's lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK), one of the most common types of skin tumors.
› Verified 5 days ago
Mr. Brian Arthur Molloy, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 10110 South 7650 East, Crow Agency, MT 59022 Phone: 406-638-3500 Fax: 406-638-3535 |